![Italian Medicines Agency](https://www.aifa.gov.it/o/aifa-theme/images/aifa/AIFA2021_Col(LR).png)
Direct communication with healthcare professionals on Sarilumab (Kevzara) - Direct communication with healthcare professionals on Sarilumab (Kevzara)
Direct communication with healthcare professionals on Sarilumab (Kevzara)
Supply for all four presentations of Kevzara® (150mg or 200mg pre-filled syringe or auto-injector) is expected to be temporarily constrained.
The shortage is due to an increase in demand and is expected to last until March 2022.
If Kevzara is not available, you should consider a suitable alternative based on availability.
Depending on the alternative, patients may need to be re-trained regarding self-administration.
Published on: 09 February 2022